1,8-萘啶-4-甲醛 | 64379-46-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 1,8-萘啶-4-甲醛
• 英文名称: 1,8-naphthyridine-4-carboxaldehyde
• 英文别名: 1,8-Naphthyridin-4-aldehyd；[1,8]naphthyridin-4-carbaldehyde；[1,8]naphthyridine-4-carbaldehyde；1,8-Naphthyridine-4-carbaldehyde
• CAS: 64379-46-0
• 化学式: C₉H₆N₂O
• mdl: MFCD06254514
• 分子量: 158.159
• InChiKey: LGCAFKJJCFELHM-UHFFFAOYSA-N

物化性质

• 沸点：
  331.3±22.0 °C(Predicted)
• 密度：
  1.299±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1,8-萘啶-4-甲醛 在 盐酸羟胺 、 sodium acetate 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以3.5 g的产率得到1,8-naphthyridine-4-carboxaldehyde oxime
  参考文献：
  名称：

  [EN] N- (4 -QUINOLINYLMETHYL) SULFONAMIDE DERIVATIVES AND THEIR USE AS ANTHELMINTICS
  [FR] DÉRIVÉS DE N- (4 -QUINOLINYLMETHYL) SULFONAMIDE ET LEUR UTILISATION EN TANT QU'ANTIHELMINTHIQUES

  摘要：

  揭示了公式1的化合物、N-氧化物及其盐，其中(1)、Q、A、R1、R2、R3和n如披露中所定义。还揭示了含有公式(1)化合物的组合物，以及治疗蠕虫感染的方法，包括向动物施用本发明的化合物或组合物的寄生虫杀灭有效量。

  公开号：

  WO2013081783A1
• 作为产物：
  描述：

  4-甲基-1,8-萘啶 在 selenium(IV) oxide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 1.5h， 以77%的产率得到1,8-萘啶-4-甲醛
  参考文献：
  名称：

  Discovery of Azetidinyl Ketolides for the Treatment of Susceptible and Multidrug Resistant Community-Acquired Respiratory Tract Infections

  摘要：

  Respiratory tract bacterial strains are becoming increasingly resistant to currently marketed macrolide antibiotics. The current alternative telithromycin (1) from the newer ketolide class of macrolides addresses resistance but is hampered by serious safety concerns, hepatotoxicity in particular. We have discovered a novel series of azetidinyl ketolides that focus on mitigation of hepatotoxicity by minimizing hepatic turnover and time-dependent inactivation of CYP3A isoforms in the liver without compromising the potency and efficacy of 1.

  DOI：

  10.1021/jm900729s

文献信息

• [EN] ANTIPROLIFERATIVE BENZO [B] AZEPIN- 2 - ONES<br/>[FR] BENZO[B]AZÉPIN-2-ONES INHIBITRICES DE LA PROLIFÉRATION
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014009495A1

  公开（公告）日：2014-01-16

  Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R1, R2, R3 and R4 are described in this application, and methods of using said compounds in the treatment of cancer.

  公开了公式(I)的化合物或其药物可接受的盐，其中W、X、Y、Z、R1、R2、R3和R4在本申请中有所描述，以及使用所述化合物治疗癌症的方法。
• AMINO-HETEROCYCLIC COMPOUNDS
  申请人：Verhoest Patrick R.

  公开号：US20090030003A1

  公开（公告）日：2009-01-29

  The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R 1 , R 2 and R 3 are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.

  该发明提供了式（I）的PDE9抑制化合物及其药用盐，其中R、R1、R2和R3如本文所定义。还提供了含有式I化合物的药物组合物，并将其用于治疗神经退行性和认知障碍，如阿尔茨海默病和精神分裂症。
• [EN] TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS<br/>[FR] COMPOSE DE BENZOPYRANNE TRICYCLIQUE EN TANT QU'AGENTS ANTI-ARRYTHMIQUES
  申请人：NISSAN CHEMICAL IND LTD

  公开号：WO2005090357A1

  公开（公告）日：2005-09-29

  This invention relates to benzopyran derivatives of formula (I) or (II), or pharmaceutically acceptable salts thereof wherein R1 and R2 are independently of each other hydrogen atom, C1-6alkyl group or C6-14aryl group, R3 is hydrogen atom or C1-6alkylcarbonyloxy group, or together with R4 forms a bond, R4 is hydrogen atom, or together with R3 forms a bond, m is an integer of 0 to 4, n is an integer of 0 to 4, V is a single bond, CR7R8, NR9, O, S, SO or SO2, R5 is hydrogen atom or C1-6alkyl group, R6 is hydrogen atom, C1-6alkyl group, C3-8cycloalkyl group, C3-8cycloalkenyl group, amino group, C1-6alkylamino group, di-C1-6alkylamino group, C6-14arylamino group, C2-9heteroarylamino group, C6-14aryl group, C2-9heteroaryl group or C2-9heterocyclyl group, A is 5-, 6- or 7-member ring fused with benzene ring, as constituent atom of the ring, oxygen atom, nitrogen atom or sulfur atom may be contained in the number of 1 to 3 alone or in a combination thereof, the number of unsaturated bond in the ring is 1, 2 or 3 including an unsaturated bond of the benzene ring to be fused, carbon atoms constituting the ring may be carbonyl or thiocarbonyl. These compounds are useful as an anti-arrhythmic agent.

  本发明涉及公式（I）或（II）的苯并吡喁衍生物，或其药学上可接受的盐，其中R1和R2分别是氢原子、C1-6烷基或C6-14芳基，R3是氢原子或C1-6烷基羰氧基，或与R4一起形成键，R4是氢原子，或与R3一起形成键，m是0到4的整数，n是0到4的整数，V是单键，CR7R8，NR9，O，S，SO或SO2，R5是氢原子或C1-6烷基，R6是氢原子，C1-6烷基，C3-8环烷基，C3-8环烯基，氨基，C1-6烷基氨基，二C1-6烷基氨基，C6-14芳基氨基，C2-9杂芳基氨基，C6-14芳基，C2-9杂芳基或C2-9杂环烷基，A是与苯环融合的5、6或7成员环，作为环的组成原子，氧原子、氮原子或硫原子可以单独或组合地包含在其中，环中的不饱和键数为1、2或3，包括与苯环融合的不饱和键，构成环的碳原子可以是羰基或硫代羰基。这些化合物可用作抗心律失常药物。
• Macrolides
  申请人：Chupak S. Louis

  公开号：US20060135447A1

  公开（公告）日：2006-06-22

  Macrolide compounds per se, as shown below and defined herein, and their use, e.g., as antibacterial and antiprotozoal agents in animals, including humans: Also disclosed are methods of preparing the compounds, intermediates, and pharmaceutical compositions thereof, and methods of treating or preventing disease by administering the compounds to subjects in need. This abstract is only an excerpt and is not limiting of the invention.

  本发明涉及以下Macrolide化合物及其定义，以及它们在动物中，包括人类中作为抗菌和抗原虫剂的用途：还公开了制备这些化合物、中间体和药物组成物的方法，以及通过将这些化合物用于需要的主体治疗或预防疾病的方法。此摘要仅为摘录，不限制本发明。
• Process for Producing Optically Active Chromene Oxide Compound
  申请人：Kondo Shoichi

  公开号：US20090043100A1

  公开（公告）日：2009-02-12

  [Problems] To provide an efficient process for producing an optically active chromene oxide compound which is an important intermediate for a benzopyran compound effective in the treatment of arrhythmia. [Means For Solving Problems] The process for producing an optically active chromene oxide compound comprises using an optically active titanium complex represented by, e.g., the formula (1) or (2) as a catalyst to asymmetrically oxidize an optically active chromene compound with high enantioselectivity in high chemical yield.

  [问题] 提供一种高效的生产光学活性的色兰氧化合物的方法，该化合物是治疗心律失常的苯并吡喃化合物的重要中间体。 [解决问题的方法] 生产光学活性的色兰氧化合物的方法包括使用光学活性钛配合物作为催化剂，例如使用公式（1）或（2）表示的光学活性钛配合物，以高对映选择性和高化学收率不对称氧化光学活性的色兰化合物。